This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Lexicon (LXRX) delivered earnings and revenue surprises of 18.75% and 680.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Lexicon Pharmaceuticals (LXRX) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Lexicon (LXRX) delivered earnings and revenue surprises of 11.76% and -99.20%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Lexicon Pharmaceuticals (LXRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Lexicon Pharmaceuticals (LXRX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Lexicon Pharmaceuticals (LXRX) stock based on the movements in the options market lately.
Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Lexicon (LXRX) delivered earnings and revenue surprises of 82.14% and 15.70%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Lexicon Pharmaceuticals (LXRX) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arena (ARNA) Tumbles as Mid-Stage Gastrointestinal Study Fails
by Zacks Equity Research
Arena's (ARNA) mid-stage study evaluating olorinab in patients with abdominal pain due to irritable bowel syndrome fails to meet primary endpoint.
Kodiak Sciences (KOD) Misses on Q4 Earnings, KSI-301 in Focus
by Zacks Equity Research
Kodiak Sciences (KOD) reports wider-than-expected loss in the fourth quarter of 2020. The company is making good progress with the development of its lead pipeline candidate, KSI-301.
Sarepta (SRPT) Q4 Loss Widens Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Sarepta (SRPT) Q4 revenues increase year over year. The company is progressing well with its pipeline.
Reata (RETA) Beats on Q4 Earnings, Submits Bardoxolone NDA
by Zacks Equity Research
Reata (RETA) reports encouraging fourth-quarter results wherein earnings and sales beat estimates. The company files NDA for lead candidate in Alport syndrome. Stock rises.
Axsome's (AXSM) Q4 Earnings Miss Estimates, Pipeline in Focus
by Zacks Equity Research
Axsome (AXSM) reports wider-than-expected loss in the fourth quarter of 2020. The company files an NDA for AXS-05 to treat major depressive disorder.
Perrigo (PRGO) Misses on Q4 Earnings, to Sell Generic Unit
by Zacks Equity Research
Perrigo (PRGO) reports dismal fourth-quarter 2020 results. The company signs deal to sell its generic drug business for $1.55 billion. Stock up.
What's in the Offing for Hewlett Packard (HPE) Q1 Earnings?
by Zacks Equity Research
Hewlett Packard's (HPE) Q1 performance likely to have benefited from higher demand for its cloud services on the ongoing digital transformation and improved supply-chain execution.
Apellis' (APLS) Q4 Earnings Rise Y/Y, Pegcetacoplan in Focus
by Zacks Equity Research
Apellis' (APLS) bottom line grows year over year in the fourth quarter of 2020 while revenues beat estimates. Main focus of the company is on lead pipeline candidate, pegcetacoplan.
Iovance (IOVA) Q4 Earnings Miss Estimates, Pipeline in Focus
by Zacks Equity Research
Iovance's (IOVA) fourth-quarter earnings miss estimates. The company is progressing well with development of its lead pipeline candidate.
Agios' (AGIO) Q4 Loss In Line, Revenues Surpass Estimates
by Zacks Equity Research
Agios' (AGIO) loss meets estimates in the fourth quarter of 2020 while revenues beat the same. Sale of leukemia drug, Tibsovo, rise both sequentially as well as year over year. Shares down.
Editas (EDIT) Misses on Q4 Earnings, Beats on Revenues
by Zacks Equity Research
Editas (EDIT) reports wider-than-expected loss in the fourth quarter of 2020 while revenues beat estimates. Pipeline development a key focus for the company.
Allogene (ALLO) Q4 Earnings Top Estimates, Pipeline Advances
by Zacks Equity Research
Allogene (ALLO) reports no revenues for the fourth quarter of 2020.
Global Blood (GBT) Q4 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Global Blood (GBT) reports a wider-than-expected loss in the fourth quarter of 2020 while revenues beat estimates.
ACADIA (ACAD) Beats on Q4 Earnings, Misses on Revenues
by Zacks Equity Research
ACADIA's (ACAD) loss narrows in the fourth quarter of 2020 while it misses estimates for revenues. Nuplazid drives year-over-year revenues.
Repligen (RGEN) Q4 Earnings & Sales Top, 2021 Outlook Bright
by Zacks Equity Research
Repligen (RGEN) reports encouraging fourth-quarter results with sales and earnings beating estimates. The company's guidance for 2021 also beats market expectations. Stock up.
Arena (ARNA) Q4 Earnings Miss Estimates, Pipeline Progresses
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) misses bottom-line estimates for fourth-quarter 2020. It initiates new study to evaluate etrasimod in patients with eosinophilic esophagitis.
Clovis (CLVS) Q4 Earnings Miss, Revenues Beat, Stock Down
by Zacks Equity Research
Clovis (CLVS) reports wider-than-expected loss for fourth-quarter 2020. Sales of the company's sole marketed drug, Rubraca, increase year over year.
Inovio (INO) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Inovio's (INO) fourth-quarter earnings call, investor focus will be on updates on the company's progress with the development of its COVID-19 vaccine candidate, INO-4800.